|
|
|||||||||
Clinical Investigation |
1 Departments of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands; 2 Department of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands; 3 Department of Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands; 4 Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands; and 5 Department of Pathology and Laboratory Medicine, University Medical Center Groningen, Groningen, The Netherlands
Correspondence: For correspondence contact: Thera P. Links, MD, PhD, Department of Endocrinology, University Medical Centre Groningen, P. O. Box 30.001, 9700 RB Groningen, The Netherlands E-mail: t.p.links{at}int.umcg.nl.
Curative treatment for recurrent medullary thyroid cancer (MTC), diagnosed by rising serum calcitonin, is surgery, but tumor localization is difficult. Therefore, the value of 18F-dihydroxyphenylanaline PET (18F-DOPA PET), 18F-FDG PET, 99mTc-V-di-mercaptosulfuricacid (DMSA-V) scintigraphy, and MRI or CT was studied. Methods: Twenty-one patients with biochemical recurrent or residual MTC underwent 18F-DOPA PET, 18F-FDG PET, DMSA-V scintigraphy, and MRI or CT. Patient- and lesion-based sensitivities were calculated using a composite reference consisting of all imaging modalities. Results: In 76% of all patients with MTC, one or more imaging modalities was positive for MTC lesions. In 6 of 8 patients with a calcitonin level of <500 ng/L, imaging results were negative. In 15 patients with positive imaging results, 18F-DOPA PET detected 13 (sensitivity, 62%; with 4.6 lesions per patient [lpp]). Morphologic imaging (n = 19) was positive in 7 (sensitivity, 37%; 4.7 lpp), DMSA-V (n = 18) in 5 (sensitivity, 28%; 1.1 lpp), and 18F-FDG PET (n = 17) in 4 (sensitivity, 24%; 1.6 lpp). In a lesion-based analysis, 18F-DOPA PET detected 95 of 134 lesions (sensitivity, 71%), morphologic imaging detected 80 of 126 (sensitivity, 64%), DMSA-V detected 20 of 108 (sensitivity, 19%), and 18F-FDG PET detected 48 of 102 (sensitivity, 30%). In 2 of 3 patients with a calcitonin/carcinoembryonic antigen (CEA) doubling time of
12 mo, 18F-FDG PET performed better than 18FDOPA PET; in the third patient, 18F-FDG PET was not performed. Conclusion: MTC lesions are best detectable when serum calcitonin was >500 ng/L. 18F-DOPA PET is superior to 18F-FDG PET, DMSA-V, and morphologic imaging. With short calcitonin doubling times (
12 mo), 18F-FDG PET may be superior.
Key Words: medullary thyroid cancer PET 18F-DOPA 18F-FDG tumor markers tumor differentiation calcitonin
COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
![]() |
H. Minn, S. Kauhanen, M. Seppanen, and P. Nuutila 18F-FDOPA: A Multiple-Target Molecule J. Nucl. Med., December 1, 2009; 50(12): 1915 - 1918. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Taieb, F. Sebag, A. Barlier, L. Tessonnier, F. F. Palazzo, I. Morange, P. Niccoli-Sire, N. Fakhry, C. De Micco, S. Cammilleri, et al. 18F-FDG Avidity of Pheochromocytomas and Paragangliomas: A New Molecular Imaging Signature? J. Nucl. Med., May 1, 2009; 50(5): 711 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-B. Fiebrich, A. H. Brouwers, L. van Bergeijk, and G. van den Berg Localization of an Adrenocorticotropin-Producing Pheochromocytoma Using 18F-Dihydroxyphenylalanine Positron Emission Tomography J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 748 - 749. [Full Text] [PDF] |
||||
![]() |
K. P. Koopmans, P. L. Jager, I. P. Kema, M. N. Kerstens, F. Albers, and R. P.F. Dullaart 111In-Octreotide Is Superior to 123I-Metaiodobenzylguanidine for Scintigraphic Detection of Head and Neck Paragangliomas J. Nucl. Med., August 1, 2008; 49(8): 1232 - 1237. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |